First Patients Dosed in Optimal-e Trial for Earlier Stage Prostate Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The international trial has managed to double the time before a new cancer treatment Álvaro Juárez currently exercises as urologist in the Hospital Vlamed Bahia de Cádiz Oncologists estimate that this year 8,000 c
Telix doses first patients in OPTIMAL-e prostate cancer trial
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") and St Vincent's Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent's Hospital in Sydney, Australia. OPTIMAL-e is a singl…
First Patients Dosed in Optimal-e Trial for Earlier Stage Prostate Cancer
First Patients Dosed in Optimal-e Trial for Earlier Stage Prostate Cancer Melbourne (Australia) and Indianapolis, IN (United States) | July 16, 2026 First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently completed …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium